Characteristics of patients in the analysis, overall and by trial
| Characteristic . | Overall (N = 737) . | AML17 (N = 348) . | AML19 (N = 389) . |
|---|---|---|---|
| Age, median (range), y | 52 (6-71) | 52 (6-70) | 52 (18-71) |
| Aged >60 y | 121 (16) | 70 (20) | 51 (13) |
| Female sex | 406 (55) | 187 (54) | 219 (56) |
| Hemoglobin (g/dL), median (IQR) | 9.00 (7.70-10.40) | 9.10 (7.90-10.30) | 8.80 (7.60-10.50) |
| White blood cell count (×109/L), median (IQR) | 22 (6-53) | 23 (9-49) | 20 (6-56) |
| Platelet count (×109/L), median (IQR) | 66 (39-110) | 66 (39-110) | 66 (39-111) |
| Bone marrow blast, median (IQR), % | 67 (40-85) | 70 (44-89) | 61 (38-80) |
| Prior myeloid malignancy | 30 (4.1) | 19 (5.5) | 11 (2.8) |
| Previous chemotherapy/radiotherapy | 11 (1.5) | 5 (1.4) | 6 (1.5) |
| Cytogenetic risk | |||
| Normal | 639 (87) | 304 (87) | 335 (86) |
| Intermediate | 71 (9.6) | 31 (8.9) | 40 (10) |
| Adverse | 9 (1.2) | 4 (1.1) | 5 (1.3) |
| Failed | 18 (2.4) | 9 (2.6) | 9 (2.3) |
| FLT3-ITD | 286 (39) | 139 (40) | 147 (38) |
| Low allelic ratio | 174 (61) | 75 (54) | 99 (68) |
| High allelic ratio | 111 (39) | 64 (46) | 47 (32) |
| FLT3 TKD | 121 (17) | 53 (15) | 68 (17) |
| Induction regimen | |||
| ADE | 99 (14) | 99 (30) | 0 (0) |
| CPX-351 | 2 (0.3) | 0 (0) | 2 (0.5) |
| DA | 434 (60) | 236 (70) | 198 (51) |
| FLAG-Ida | 188 (26) | 0 (0) | 188 (48) |
| Gemtuzumab with induction | 378 (52) | 116 (34) | 262 (67) |
| Allogeneic transplant | |||
| Transplant in CR1 | 167 (23) | 68 (20) | 99 (25) |
| Transplant at other stage | 131 (18) | 72 (21) | 59 (15) |
| No transplant | 439 (60) | 208 (60) | 231 (59) |
| Characteristic . | Overall (N = 737) . | AML17 (N = 348) . | AML19 (N = 389) . |
|---|---|---|---|
| Age, median (range), y | 52 (6-71) | 52 (6-70) | 52 (18-71) |
| Aged >60 y | 121 (16) | 70 (20) | 51 (13) |
| Female sex | 406 (55) | 187 (54) | 219 (56) |
| Hemoglobin (g/dL), median (IQR) | 9.00 (7.70-10.40) | 9.10 (7.90-10.30) | 8.80 (7.60-10.50) |
| White blood cell count (×109/L), median (IQR) | 22 (6-53) | 23 (9-49) | 20 (6-56) |
| Platelet count (×109/L), median (IQR) | 66 (39-110) | 66 (39-110) | 66 (39-111) |
| Bone marrow blast, median (IQR), % | 67 (40-85) | 70 (44-89) | 61 (38-80) |
| Prior myeloid malignancy | 30 (4.1) | 19 (5.5) | 11 (2.8) |
| Previous chemotherapy/radiotherapy | 11 (1.5) | 5 (1.4) | 6 (1.5) |
| Cytogenetic risk | |||
| Normal | 639 (87) | 304 (87) | 335 (86) |
| Intermediate | 71 (9.6) | 31 (8.9) | 40 (10) |
| Adverse | 9 (1.2) | 4 (1.1) | 5 (1.3) |
| Failed | 18 (2.4) | 9 (2.6) | 9 (2.3) |
| FLT3-ITD | 286 (39) | 139 (40) | 147 (38) |
| Low allelic ratio | 174 (61) | 75 (54) | 99 (68) |
| High allelic ratio | 111 (39) | 64 (46) | 47 (32) |
| FLT3 TKD | 121 (17) | 53 (15) | 68 (17) |
| Induction regimen | |||
| ADE | 99 (14) | 99 (30) | 0 (0) |
| CPX-351 | 2 (0.3) | 0 (0) | 2 (0.5) |
| DA | 434 (60) | 236 (70) | 198 (51) |
| FLAG-Ida | 188 (26) | 0 (0) | 188 (48) |
| Gemtuzumab with induction | 378 (52) | 116 (34) | 262 (67) |
| Allogeneic transplant | |||
| Transplant in CR1 | 167 (23) | 68 (20) | 99 (25) |
| Transplant at other stage | 131 (18) | 72 (21) | 59 (15) |
| No transplant | 439 (60) | 208 (60) | 231 (59) |
Data are given as number (percentage) unless otherwise indicated.
ADE, cytarabine, daunorubicin, and etoposide; CR1, first complete remission; DA, daunorubicin and cytarabine; FLAG-Ida, fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubucin; IQR, interquartile range; TKD, tyrosine kinase domain.